Single-agent mitomycin for advanced non-small cell lung cancer.
In the treatment of patients with advanced non-small cell lung cancer with chemotherapy, there is no consensus concerning the optimum regimen. Survival is poor and the activity of drugs has to be balanced against toxicity. There is therefore continued interest in the use of single-agent chemotherapy for this condition. I report the treatment of non-small cell lung cancer with mitomycin. In 20 patients, four responses were observed, giving a response rate of 20% (95% confidence interval (CI) 3-37); median survival was 26 weeks (95% CI 13-30). One patient who presented with bone and liver metastases survived for 27 months after treatment.
Snee
M
M
Mid Kent Oncology Centre, Maidstone General Hospital, Maidstone, UK.
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality*; D004739:England; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D010166:Palliative Care; D016019:Survival Analysis
D000903:Antibiotics, Antineoplastic; D016685:Mitomycin